Metrics as of 10/14/2026, 11:47 PM (Berlin time), refresh in progress.
Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. The company operates through two primary segments, which are Diabetes and Obesity Care and Rare Disease. The Diabetes and Obesity Care segment includes therapy areas for…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
1D
+0.5%
1W
+0.2%
1M
-9.4%
6M
-1.6%
YTD
-21.3%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~95% stronger price swings than usual
FREE FLOAT
–
FLOAT SHARES
3,145,602,804
AVG. DAILY VOLUME (30D)
15,954
Novo Nordisk A/S is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in Denmark.
The CEO is Maziar Mike Doustdar, the company employs around 68,794 people.
The IPO was on 24/11/2025; the stock trades on TSX under the ticker NOVO.TO.
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 95% stronger than usual.
Yes. The last dividend was CA$0.24 per share, ex-date 17/08/2026, paid on 25/08/2026.
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Roche Holding, Amgen, Gilead Sciences and Pfizer.
Clicking "Analyze stock" lets five strategies assess Novo Nordisk A/S against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.